Related Experiment Video

Updated: May 23, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Management of hepatocellular carcinoma: beyond sorafenib

Stephen L Chan1, Tony Mok, Brigette B Y Ma

  • 1State Key Laboratory in Oncology in South China, Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.

Current Oncology Reports
|March 22, 2012
PubMed

Insights

Sorafenib offers new hope for hepatocellular carcinoma (HCC) patients. Research now focuses on novel targeted therapies and combinations to improve HCC treatment outcomes beyond current standards.

Area of Science:

  • Hepatobiliary cancers
  • Oncology
  • Translational medicine

Background:

  • Hepatocellular carcinoma (HCC) management has advanced with sorafenib.
  • Tumor progression in HCC is linked to deregulated signaling pathways and epigenetic factors.
  • Improved treatment strategies are needed to enhance patient outcomes.

Purpose of the Study:

  • To review the current clinical development of HCC treatments.
  • To discuss future research directions in HCC therapy.
  • To explore novel agents and combination therapies for HCC.

Main Methods:

  • Review of current clinical trial data for HCC treatments.
  • Analysis of emerging research on HCC pathogenesis.
  • Synthesis of information on targeted therapies and transarterial chemoembolization (TACE).

Main Results:

  • Sorafenib has established a new benchmark in HCC treatment.
  • Targeted therapies and combination strategies show promise for improved outcomes.
  • Ongoing research is identifying novel agents for HCC management.

Conclusions:

  • Novel targeted therapies and combination treatments represent the future of HCC management.
  • Continued research into signaling pathways and epigenetic mechanisms is crucial.
  • The goal is to surpass the efficacy of sorafenib in treating HCC.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...